BioPorto A/S (CPH:BIOPOR) CEO Peter Eriksen tells Proactive 2021 "will be a pivotal year" for the Danish in-vitro diagnostics company.
Eriksen says the group will submit several applications to FDA and European health care authorities. He says if these are successful they will lay a very strong foundation for commercialization and the next phase in the development of the company.